Research Groups

Federica Benvenuti

Cellular Immunology

Group Leader

Research Interests and Description
Group Members

Federica Benvenuti

International Centre for Genetic Engineering and Biotechnology
Padriciano 99
34149 Trieste, Italy

E-mail: benvenutiicgeb.org
Lab tel: +39-040-3757389
Office fax: +39-040-226555

Education

University of Trieste, MSc in Molecular Biology, 1995
International School for Advanced Studies, ICGEB, PhD in Molecular Genetics and Biotechnology, 2000

Career History

Since January 2010, Group Leader, Cellular Immunology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
2005-2009, Postdoc, ICGEB Trieste, Italy
2001-2004, Postdoc, Institut Curie, Paris, France
1996-2000, PhD student, ICGEB Trieste, Italy
1990-1995, Undergraduate student, Faculty of Science, University of Trieste

Scientific Activity

The main research interest is the cell biology of antigen presentation and intracellular trafficking for regulation of T cell priming and cytokine responses, in specialized subsets of myeloid cells. First as a post-doc and later as PI, F. Benvenuti developed the tools to investigate remodeling of the actin cytoskeleton and membrane trafficking proteins in dendritic cells during priming of T lymphocytes, identifying important molecular regulators that determine the efficiency of antigen presentation. The expertise in fundamental aspects of DCs biology has then been applied to altered adaptive and innate responses in pathological conditions. Her team discovered some of the cellular defects that underlie bad functioning of dendritic cells in a rare immuno-deficiency, Wiskott-Aldrich syndrome. Most recently her group started to characterize the mechanism leading to suppression of dendritic cell subsets in lung cancer.

F. Benvenuti serves as a reviewer for several scientific journals and Grant Award Committees for the ANR (France) and ERC. She is regularly involved in PhD award committee at several national and international Institutions (IST, Vienna; Universite’ Paris IIV and Paris Descartes; Open University).

Selected Publications

Cervantes-Luevano KE, Caronni N, Castiello MC, Fontana E, Piperno G, Naseem A, Uva P, Bosticardo M, Marcovecchio GE, Notarangelo LD, Cicalese MP, Aiuti A, VillaA, Benvenuti F. Neutrophils drive type-I interferon production and autoantibodies in Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2018 Feb 12. pii: S0091-6749(18)30207-0. doi: 10.1016/j.jaci.2017.11.063. PubMed PMID: 29447842.

Caronni N, Simoncello F, Stafetta F, Guarnaccia C, Ruiz-Moreno JS, Opitz B, Galli T, Proux-Gillardeaux V, Benvenuti F. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 2018 Jan 23. pii: canres.1307.2017. doi: 10.1158/0008-5472.CAN-17-1307. PubMed PMID: 29363545.

Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E, Shacham S, Valsasina B, Cucchi U, Pippione AC, Lolli ML, Giabbai B, Storici P, Carloni P, Rossetti G, Benvenuti F, Bello E, D'Incalci M, Cappuzzello E, Rosato A, Del Sal G. “A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action”. Nat Commun 2017. Jun 9;8:15772. doi: 10.1038/ncomms15772

Castiello MC, Pala F, Sereni L, Draghici E, Inverso D, Sauer AV, Schena F, Fontana E, Radaelli E, Uva P, Cervantes-Luevano KE, Benvenuti F, Poliani PL, Iannacone M, Traggiai E, Villa A, Bosticardo M. “In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells”. Front Immunol. 2017 May 2;8:490. doi: 10.3389/fimmu.2017.00490.

Ottaviani G, Martinelli V, Rupel K, Caronni N, Naseem A, Zandon√† L, Perinetti, G, Gobbo M, Di Lenarda R, Bussani R, Benvenuti F, Giacca M, Biasotto M, Zacchigna S. “Laser Therapy Inhibits Tumor Growth in Mice by Promoting Immune Surveillance and Vessel Normalization”. EBioMedicine. 2016 Sep;11:165-172. doi: 10.1016/j.ebiom.2016.07.028. Epub 2016 Jul 25.

Benvenuti F. “The dendritic cell synapse: a life dedicated to T cell activation”. Front Immunol. 2016 Mar 7,7:70. Doi:10.3389/fimmu.2016.00070.eCollection 2016.

Chiaruttini, G., Piperno, G.M., Jouve, M., De Nardi, F., Larghi, P., Peden, A.A., Baj, G., Müller, S., Valitutti, S., Galli, T., and Benvenuti, F. “The SNARE VAMP7 regulates exocytic trafficking of Interleukin-12 in dendritic cells. Cell Rep. 2016. 14. 10.1016/j.celrep.2016.02.055.

MarinoKallikourdis , Antonella Viola A, Federica Benvenuti. “Human Immunodeficiencies Related to Defective APC/T Cell Interaction”. Front Immunology. 2015. 6:433. doi: 10.3389/fimmu.2015.00433.

Mayrel Labrada, Isabel Pablos, Francesca Prete, Giselle Hevia, Marilyn Clavell, Federica Benvenuti & Luis E Fernández. “Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine”. Human Vaccines & Immunotherapeutics. 2014.

Mion F, Benvenuti F, Pucillo C, Vitale G . “Use of cocultures for the study of cellular interactions influencing B cell regulatory functions”. Methods Mol Biol. 2014. 1190:163-79. doi: 10.1007/978-1-4939-1161-5_12. 10(8):2312-20.

Rustighi, A., A. Zannini, L. Tiberi, R. Sommaggio, S. Piazza, G. Sorrentino, S. Nuzzo, A. Tuscano, V. Eterno, F. Benvenuti, L. Santarpia, I. Aifantis, A. Rosato, S. Bicciato, A. Zambelli, and G. Del Sal. “Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast”. EMBO Mol Med. 2014. 6:99-119.

Prete, F., M. Catucci, M. Labrada, S. Gobessi, M. C. Castiello, E. Bonomi, A. Aiuti, W. Vermi, C. Cancrini, A. Metin, S. Hambleton, R. Bredius, L. D. Notarangelo, M. van der Burg, U. Kalinke, A. Villa, and F. Benvenuti. “Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells”. J Exp Med 2013. 210:355-374.

Savino, B., M. G. Castor, N. Caronni, A. Sarukhan, A. Anselmo, C. Buracchi, F. Benvenuti, V. Pinho, M. M. Teixeira, A. Mantovani, M. Locati, and R. Bonecchi.. “Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6”. Blood. 2012. 119:5250-5260.

Catucci, M., F. Prete, M. Bosticardo, M. C. Castiello, E. Draghici, M. Locci, M. G. Roncarolo, A. Aiuti, F. Benvenuti, and A. Villa. 2012. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome. Gene Ther. 2012 19:1150-1158.

Pulecio, J., J. Petrovic, F. Prete, G. Chiaruttini, A. M. Lennon-Dumenil, C. Desdouets, S. Gasman, O. R. Burrone, and F. Benvenuti. 2010. “Cdc42-mediated MTOC polarization in dendritic cells controls targeted delivery of cytokines at the immune synapse”. J Exp Med  2010. 207:2719-2732.

Tagliani, E., P. Guermonprez, J. Sepulveda, M. Lopez-Bravo, C. Ardavin, S. Amigorena, F. Benvenuti, and O. R. Burrone.”Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells”. J Immunol. 2008. 180:3201-3209.

Pulecio, J., E. Tagliani, A. Scholer, F. Prete, L. Fetler, O. R. Burrone, and F. Benvenuti. 2008. “Expression of Wiskott-Aldrich syndrome protein in dendritic cells regulates synapse formation and activation of naive CD8+ T cells”. J Immunol 181:1135-1142.

Cesco-Gaspere, M., F. Benvenuti, and O. R. Burrone.”BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies”. Cancer Immunol Immunother. 2005. 54:351-358.

Benvenuti, F., C. Lagaudriere-Gesbert, I. Grandjean, C. Jancic, C. Hivroz, A. Trautmann, O. Lantz, and S. Amigorena. “Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes”. J Immunol. 2005. 172:292-301.

Benvenuti, F., S. Hugues, M. Walmsley, S. Ruf, L. Fetler, M. Popoff, V. L. Tybulewicz, and S. Amigorena. “Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming”. Science. 2004. 305:1150-1153.

Benvenuti, F., M. Cesco-Gaspere, and O. R. Burrone. 2002. “Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Front Biosci 7:d228-234.

Benvenuti, F., and O. R. Burrone. 2002. Genetic vaccination for the immunotherapy of B-cell malignancies”. Curr Gene Ther 2:235-242.

Benvenuti, F., and O. R. Burrone. “Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants”. Gene Ther. 2001. 8:1555-1561.

Benvenuti, F., O. R. Burrone, and D. G. Efremov.”Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection”. Gene Ther. 2000. 7:605-611.

Cod. Fisc. 90031700322 tl_files/trieste pics/5permille .png

AREA Science Park
Padriciano 99
34149 Trieste, ITALY
Tel: +39-040-37571
Fax: +39-040-226555
icgebicgeb.org
Address book

 

tl_files/iTunes_Badge_Color_master_10251024.png

 


tl_files/FB.png
 tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png